The Chemotherapy Question Nobody Asked in Four Major Endometrial Cancer Trials
RUBY, NRG-GY018, AtTEnd, and DUO-E4 all proved immunotherapy works in dMMR endometrial cancer. None of them tested whether chemotherapy...
RUBY, NRG-GY018, AtTEnd, and DUO-E4 all proved immunotherapy works in dMMR endometrial cancer. None of them tested whether chemotherapy...
A 6-year-old died after an unreported gene-editing trial at Shanghai Xinhua Hospital. With 1,033 CGT IITs active in China,...
FDA's reviews of Zolgensma, Luxturna, and Hemgenix reveal critical gaps in AAV trial design, CMC standards, and long-term safety...
PROSpect enrolled 424 children across 75 PICUs in 18 countries to test prone positioning and HFOV in PARDS, and...
EMA's CHMP recommended 6 new medicines and 5 label expansions in its Oct 12-15 cycle. Here's what daraxonrasib's pancreatic...
TRIUMPH-2's Phase 3 data on retatrutide in 1,152 T2D patients challenges every assumption sponsors hold about GLP-1 trial design...
A Nature Biotechnology retinal AI model detects preeclampsia and gestational hypertension risk non-invasively, and its trial implications go far...
NEJM publishes evERA Breast Cancer trial data showing giredestrant plus everolimus superiority in HR+ advanced breast cancer, here's what...
WILLOW Cohort B's p=0.14 masked a 58% BICLA response at the lowest dose. The drug worked. The endpoint couldn't...
EPoS II RCT finds 5-year colonoscopy surveillance noninferior to 3-year for high-risk adenoma patients, forcing a rethink of global...